PLEKHM2

Across TCGA pan-cancer cohorts, PLEKHM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHM2 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLEKHM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PLEKHM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.920	0.777	.003	36	view →
LUAD	OS	Tertile	III,IV	0.317	0.731	.036	8	view →
CCRCC	DFS	Median	III,IV	1.000	0.821	.020	7	view →
GBM	OS	Tertile	All	0.356	0.661	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLEKHM2–HNSC (OS)

Open the HNSC breakdown →